$BPTS News

Last published 2y ago

2y agoBPTSBiophytis Publishes First-Half Financial Results and Provides an Update on its Business ActivitiesACCESS NewswirePARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Biophytis SA , a clinical-stage biotechnology company focused on developing treatments
2y agoBPTSBiophytis Obtains IND Approval from the FDA to Start its Phase 2 OBA Study in ObesityACCESS NewswirePARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 11, 2024 / Biophytis SA , , a clinical-stage biotechnology company specialized in the development of
2y agoBPTSBiophytis Presented its Phase 2-3 COVA Study Results in Severe Forms of Covid-19 at the WCID in ParisACCESS NewswirePARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 1, 2024 / Biophytis SA , , a clinical-stage biotechnology company specialized in the
2y agoBPTSBiophytis grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at up to €108 MillionACCESS NewswireBiophytis to receive upfront and milestones payments for a total amount up to €108 million, as well as double-digit royaltieson future sales of the productAgreement covers commercialization of BIO101 in Latin
2y agoBPTSBiophytis Extends Its Contract With Atlas to Secure Financing for Its Business ActivitiesACCESS NewswireImportant note: Biophytis has set up financing in the form of Bonds redeemable in cash and in new and existing shares with the company Atlas, which, after having received the shares resulting from the conversion
2y agoBPTSBiophytis Announces the Successful Industrial Transfer of BIO101 (20-hydroxyecdysone) Production by its Service Provider SeqensACCESS NewswirePARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / June 12, 2024 / Biophytis SA , , a clinical-stage biotechnology company specialized in the development of
2y agoBPTSBiophytis Announces Filing of an IND Application with the US FDA for its Phase 2 Study in ObesityACCESS NewswirePARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 10, 2024 / Biophytis SA , , a clinical-stage biotechnology company specialized in the development of
2y agoBPTSCombined General Meeting of June 24, 2024ACCESS NewswirePARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 7, 2024 / Biophytis SA , , a clinical-stage biotechnology company specialized in the development
2y agoBPTSBiophytis Announces the Design of its Phase 2 OBA Clinical Study in ObesityACCESS NewswirePARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / May 14, 2024 / Biophytis SA , , a clinical-stage biotechnology company specialized in the development of
2y agoBPTSBiophytis is Deploying its Partnership Strategy in ObesityACCESS NewswirePARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 29, 2024 / Biophytis SA , , a clinical-stage biotechnology company specialized in the development of
2y agoBPTSBiophytis Announces Transfer of ADSs to OTC MarketACCESS NewswireADSs delisted from Nasdaq, which will result in meaningful savingsADSs transferred to OTC Pink market; Company will apply to trade on OTCQB marketBiophytis remains listed on Euronext Growth Paris as its primary trading
2y agoBPTSBiophytis Announces Ratio Change Under its American Depositary Receipt ("ADR") ProgramACCESS NewswirePARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 19, 2024 / Biophytis SA , , a clinical-stage biotechnology company specialized in
2y agoBPTSBiophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in ObesityACCESS NewswireIND to be filed with the FDA in the coming weeksPARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 18, 2024 / Biophytis SA , , a
2y agoBPTSBiophytis Announces Its 2023 Financial Results and Provides an Update on Its Business ActivitiesACCESS NewswirePARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 8, 2024 / Biophytis SA , , a clinical-stage biotechnology company specialized in the
2y agoBPTSBiophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)ACCESS NewswirePromising preclinical results obtained in obesity support the OBA Phase 2 clinical study expected to start mid-2024PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 8, 2024 / Biophytis SA ,
2y agoBPTSResults of the Combined General Meeting on April 2, 2024ACCESS NewswireAll resolutions presented by the Company have been adoptedPARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 4, 2024 / Biophytis SA ,, , a
2y agoBPTSBiophytis Presented its Phase 3 Protocol in the Treatment of SarcopeniaACCESS NewswirePARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / March 22, 2024 / Biophytis SA , , a clinical-stage biotechnology company specialized in the
2y agoBPTSBiophytis Announces Receipt of Nasdaq NoticeACCESS NewswirePARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / November 17, 2023 / Biophytis SA , , a clinical-stage biotechnology company specialized in the
3y agoBPTSBiophytis and Innovation Solutions Pharma Sign a Partnership Agreement to Accelerate Market Access for Sarconeos (BIO101) in BrazilACCESS NewswirePARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / October 30,2023 / Biophytis SA , , a clinical-stage biotechnology company specialized in the development of therapeutics
3y agoBPTSBiophytis Receives Notice of Delisting From Nasdaq and Announces It Will Request a Hearing Before the Nasdaq Hearings PanelACCESS NewswirePARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / October 27, 2023 / Biophytis SA , , a clinical-stage biotechnology company specialized in the development of
3y agoBPTSBiophytis Releases Its Half-Yearly Accounts as of 30 June 2023 and Provides an Update on Its OperationsACCESS NewswireStart of industrial development of Sarconeos with a view to market access in severe forms of Covid-19 Approvals to start the Phase 3 trial in the United States and Belgium in sarcopenia , a world
3y agoBMY BPTS ONCY RNAZ+1Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors RisePR NewswirePALM BEACH, Fla. , Sept. 26, 2023 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - There has been a rise in the prevalence of cancer in the past several years. Overall, there is a rapid increase in the prevalence
3y agoBPTSBiophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)ACCESS NewswirePARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 25, 2023 / Biophytis SA , , a clinical-stage biotechnology company specialized in the development of therapeutics that are
3y agoBPTSBiophytis Provides an Update on its Early Access Programs for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19ACCESS NewswirePARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 19, 2023 / Biophytis SA , , a clinical-stage biotechnology company specialized in the development of therapeutics that are
3y agoBPTSBiophytis Strengthens its Management Team with the Appointment of its Chief Business OfficerACCESS NewswirePARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 14, 2023 / Biophytis SA , , a clinical-stage biotechnology company specialized in the development of therapeutics that are
3y agoBPTSBiophytis Obtains FDA Authorization to Initiate the SARA-31 Phase 3 Study in SarcopeniaACCESS NewswirePARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 11,2023 / Biophytis SA , , a clinical-stage biotechnology company specialized in the development of
3y agoBPTSBiophytis Announces Next Regulatory Steps in Europe and the United States for its COVA ProjectACCESS NewswirePARIS FRANCE and CAMBRIDGE, MA / ACCESSWIRE / August 16, 2023 / Biophytis SA , , a clinical-stage biotechnology company specialized in the development of therapeutics
3y agoBPTSBiophytis Receives a Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in EuropeACCESS NewswirePARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / August 8, 2023 / Biophytis SA , , a clinical-stage biotechnology company specialized in the development of therapeutics
3y agoBPTSBiophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19ACCESS NewswirePARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / July 20, 2023 / Biophytis SA , , a clinical-stage biotechnology company specialized in the development of therapeutics
3y agoBPTSBiophytis Announces $3.8 Million Registered Direct OfferingACCESS NewswirePARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / July 19, 2023 / Biophytis SA , , a clinical-stage biotechnology company focused on the
3y agoBPTSBiophytis and SEQENS Sign a Partnership to Produce Sarconeos (BIO101) Active CompoundACCESS NewswirePARIS, FRANCE / ACCESSWIRE / July 18, 2023 / Biophytis SA , , a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at
3y agoBPTSBiophytis Has Filed with The FDA For Authorization to Initiate SARA-31 Phase 3 Study in SarcopeniaACCESS NewswirePARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / July 10, 2023 / Biophytis SA , a clinical-stage biotechnology company specializing in the
3y agoBPTSBiophytis: Results of the Annual General Meeting on June 16, 2023 All Resolutions Presented by the Company Have Been AdoptedACCESS NewswireRESULTS OF THE ANNUAL GENERAL MEETING ON JUNE 16, 2023ALL RESOLUTIONS PRESENTED BY THE COMPANY HAVE BEEN ADOPTEDPARIS FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 16, 2023 / Biophytis SA ,
3y agoBPTSBiophytis has Filed with the French National Authority for Health (HAS) an Application for Early Access Authorisation (EAA) for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19ACCESS NewswirePARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / May 26, 2023 / Biophytis SA , a clinical-stage biotechnology company focused on the development
3y agoBPTSBiophytis Presented Positive Results of Phase 2-3 COVA Study At The American Thoracic Society International ConferenceACCESS NewswirePARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / May 25, 2023 / Biophytis SA , a clinical-stage biotechnology company focused on the development
3y agoBPTSBiophytis has Filed with the EMA for Authorization to Initiate SARA-31 Phase 3 Study in SarcopeniaACCESS NewswirePARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / May 15, 2023 / Biophytis SA , a clinical-stage biotechnology company focused on the development
3y agoBPTSSuccessful Capital Increase for Biophytis with €2.3 million RaisedACCESS NewswireSuccess of the placement with professional investors, historical supporters of the Company, for an amount of €1.9M.Strong participation of retail investors via the PrimaryBid platform with an offer allocated to
3y agoBPTSBiophytis Launches a Round of Fundraising for Approximately 2 Million EurosACCESS NewswireCapital increases as part of a global offering comprising an offer reserved for professional investors and a public offering for retail investors through the PrimaryBid platform.The PrimaryBid offering will close on May
3y agoBPTSBiophytis has Requested a Pre-Submission Meeting with the EMA for the Marketing Authorisation of Sarconeos (BIO101) for the Treatment of COVID-19ACCESS NewswirePARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / May 9, 2023 / Biophytis SA , a clinical-stage biotechnology company focused on the development
3y agoBPTSBiophytis Strengthens its Management TeamACCESS NewswireAppointment of Chiara Baccelli as Director of Pharmaceutical Operations and Quality AssuranceAppointment of Nicolas Fellmann as Chief Financial OfficerPARIS, FRANCE and CAMBRIDGE, MA / ACCESSWORE / May 2, 2023 /
3y agoBPTSBiophytis Announces Receipt of Nasdaq NoticeACCESS NewswirePARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 28, 2023 / Biophytis SA , , a clinical-stage biotechnology company focused on the
3y agoBPTSBiophytis Regains Compliance with NASDAQ Minimum Bid Price RequirementACCESS NewswirePARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 19, 2023 / Biophytis SA , a clinical-stage biotechnology company focused on the
3y agoBPTSBiophytis Announces 2022 Financial Results and 2023 PerspectivesACCESS Newswire€11.1M of available cash and equivalents on December 31, 2022, and financing instruments for a total of €22M allowing financial visibility beyond mid 2024Positive results of the Phase 2-3 COVA study for the
3y agoBPTSBiophytis: Results of the Combined General Meeting on April 17, 2023ACCESS NewswireAdoption of all resolutionsReduction of the nominal value of the share to 0.01 euroPARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 18, 2022 / Biophytis SA , ("Biophytis" or
3y agoBPTSBiophytis: The Combined General Meeting Will Be Held on Second Call on April 17, 2023ACCESS NewswirePARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / March 30, 2023 / Biophytis SA , a clinical-stage biotechnology company focused on the
3y agoBPTSBiophytis: Biophytis Presented Sarconeos (BIO101) As A Possible Treatment Candidate for Long COVID After Hospitalization During The 13th Annual International Conference on Frailty and Sarcopenia ReseaACCESS NewswireBiophytis presented Sarconeos as a possible treatment candidate for long COVID after hospitalization during the 13th annual International Conference on Frailty and Sarcopenia Research PARIS, FRANCE /
4y agoBPTS PARIS:ALBPSBiophytis Participates in H.C. Wainwright 24th Annual Global Investment ConferenceACCESS NewswirePARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 15, 2022 / Biophytis SA (NasdaqCM:BPTS)(PARIS:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative pro
4y agoBPTS PARIS:ALBPSThe Paris Court of Appeal Rules in Favour of Biophytis in the Case Against Negma Group LtdACCESS NewswireOn July 16th July 2021, the Paris Court had imposed on Biophytis a penalty payment of EUR 1,500,000 in favour of Negma Group Ltd, following a judgment of the Paris Commercial Court On September 8th 2022, the Paris Court of Appeal partially reversed the
4y agoBPTS PARIS:ALBPSBiophytis Announces Very Promising Top Line Results of its Phase 2-3 COVA Clinical Study in COVID-19-Related Respiratory FailureACCESS NewswirePARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 7th, 2022 / Biophytis SA (NasdaqCM:BPTS)(PARIS:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative pr
4y agoBPTS PARIS:ALBPSBiophytis: Convening of Another Combined General Meeting at a Later DateACCESS NewswirePARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 3, 2022 / Biophytis SA (NASDAQ:BPTS)(PARIS:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes